Detoxification of the Liver In PSC (Dolphin)

Inclusion Criteria:

• A diagnosis of PSC for at least 6 months based upon cholangiography (ERCP or MRCP)demonstrating intrahepatic and/or extrahepatic biliary strictures, beading orirregularity consistent with PSC.

• ALP > 1.5 times the upper limit of normal (ULN) at screening.

• Subject must either be on a stable dose of ursodeoxycholic acid for > 6 months priorto screening or have been discontinued > 4 weeks prior to screening (enrollment ofpatients who are on UDCA will be limited to 60% of all enrolled patients).

Exclusion Criteria:

• Anticipated need for liver transplant within one year as determined by Mayo PSC riskscore

• Evidence of decompensated liver disease such as variceal bleeding, ascites, orhepatic encephalopathy.

• Evidence of advanced liver disease including MELD score > 10, bilirubin > 3.0,platelet count < 100,000; or INR > 1.4

• Concomitant chronic liver disease including alcohol related liver disease, chronichepatitis B or C infection, haemochromatosis, Wilson's disease, alpha1-antitrypsindeficiency, non-alcoholic steatohepatitis, autoimmune hepatitis, or primary biliarycholangitis

• Secondary causes of sclerosing cholangitis

• Patients who have a confirmed malignancy or cancer within 5 years exceptnon-melanoma skin cancers

• Treatment with any investigational agents, within two months or 5 half-lives of theinvestigational product, whichever is longer.

• Active illicit drug or more than moderate alcohol consumption.

• Evidence of bacterial cholangitis within 6 months of enrollment

• In patients with Ulcerative Colitis, or, if Crohn's disease, a need for additionaltherapy at time of screening.

• Chronic kidney injury (eGFR < 60)

• Pregnancy or lactation

• Uncontrolled hypertension with a systolic BP > 140 and a systolic BP > 90

• Prohibited medications: current use of vitamin C and prednisone

• Patients with a history or risk of cardiovascular conditions, including arrhythmia,long QT syndrome, congestive heart failure, stroke, or coronary artery disease

• Patients with a history of kidney stones

• Congenital or acquired immunodeficiencies

• Other comorbidities including: diabetes mellitus, systemic lupus

• An episode of acute cholangitis within 4 weeks of screening